Concepedia

Claudio Gimpelewicz

CG

Statistics

Publications

36

Citations

2.2K

H-Index

22

Active since

2004

Affiliations

Novartis (Switzerland)(Current)

University of California, San Francisco

San Francisco VA Medical Center

University of Brescia

University of California San Diego

Claudio Gimpelewicz is an author at Novartis (Switzerland) specializing in medicine, cardiology, and heart failure.

ORCID

Publications per year

2004–2025

36

Publications

36

Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure

Mihai Gheorghiade, Michael Böhm, Stephen J. Greene et al. · JAMA · 2013 · 327 citations · Full text

, , +17

Effects of Serelaxin in Patients with Acute Heart Failure

Marco Metra, John R. Teerlink, Gad Cotter et al. · New England Journal of Medicine · 2019 · 268 citations · Full text

, , +15

Direct Renin Inhibition in Addition to or as an Alternative to Angiotensin Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale and Design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) Study

Henry Krum, Barry M. Massie, William T. Abraham et al. · European Journal of Heart Failure · 2010 · 127 citations · Full text

, , +16

Serelaxin in Addition to Standard Therapy in Acute Heart Failure: Rationale and Design of the RELAX-AHF-2 Study

John R. Teerlink, Adriaan A. Voors, Piotr Ponikowski et al. · European Journal of Heart Failure · 2017 · 122 citations · Full text

, , +11

Drug Discovery for Kinetoplastid Diseases: Future Directions

Srinivasa P. S. Rao, Michael P. Barrett, Glenn Dranoff et al. · ACS Infectious Diseases · 2018 · 110 citations · Full text

, , +17

1–5 of 36